Apollo Drug Discovery Team

Home  /  Apollo People  /  Dr Richard Mason
Richard Mason

DR RICHARD MASON MBA

Head of Johnson & Johnson Innovation, London

Richard is the head of Johnson & Johnson Innovation, London. He joins Johnson & Johnson Innovation from XO1 Limited, where he served as CEO until the company was acquired by Janssen in March 2015. Prior to his role at XO1, Richard was Head of Strategy and Business Development at specialist pharmaceutical and medical device company BTG Plc, where he led its transformation into a leading interventional medicine company through multiple acquisitions.

Richard also served as an Executive-in-Residence for Advent Venture Partners LLC where he was a turnaround CEO for several portfolio companies. Previously he was Senior Vice President, Business Development at Cambridge Antibody Technology (CAT).

Richard trained in medicine at the St Bartholomew’s Hospital Medical College and worked in clinical practice in internal medicine before entering the biotechnology industry. He also has a degree in immunology from UCL and an MBA from The Judge Business School, University of Cambridge, where he is currently a Fellow in Healthcare Management and teaches the MBA elective in biotechnology and pharmaceuticals.

Richard resides near Cambridge, UK. In his spare time Richard enjoys skiing, running, flying and sailing.

Apollo aims to integrate academic research
and the biopharma industry